Free Trial
NYSE:CHRO

Chromocell Therapeutics (CHRO) Stock Price, News & Analysis

Chromocell Therapeutics logo
$1.25 +0.11 (+9.65%)
Closing price 05/1/2025 04:00 PM Eastern
Extended Trading
$1.25 0.00 (0.00%)
As of 07:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Chromocell Therapeutics Stock (NYSE:CHRO)

Key Stats

Today's Range
$1.06
$1.28
50-Day Range
$1.14
$2.28
52-Week Range
$0.45
$3.80
Volume
70,638 shs
Average Volume
428,213 shs
Market Capitalization
$7.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Receive CHRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chromocell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CHRO Stock News Headlines

Ligand subsidiaries, Chromocell Therapeutics to merge
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Chromocell Therapeutics Corp (CHRO)
Channel Therapeutics Corporation (CHRO)
See More Headlines

CHRO Stock Analysis - Frequently Asked Questions

Chromocell Therapeutics' stock was trading at $0.6410 at the beginning of 2025. Since then, CHRO shares have increased by 95.0% and is now trading at $1.25.
View the best growth stocks for 2025 here
.

Chromocell Therapeutics (CHRO) raised $7 million in an initial public offering (IPO) on Friday, February 16th 2024. The company issued 1,100,000 shares at $6.00 per share.

Shares of CHRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
5/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:CHRO
Previous Symbol
NYSE:CHRO
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($1.65) per share
Price / Book
-0.76

Miscellaneous

Free Float
5,039,000
Market Cap
$7.63 million
Optionable
N/A
Beta
4.41
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NYSE:CHRO) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners